bruce cree, md, phd, mas: inebilizumab in neuromyelitis optica spectrum disorder
Published 4 years ago • 600 plays • Length 3:10Download video MP4
Download video MP3
Similar videos
-
4:41
bruce cree, md, phd, mas: inebilizumab for nmosd treatment
-
4:15
bruce cree, md, phd, mas: the future landscape in nmosd
-
3:46
bruce cree, md, phd, mas: insights from the n-momentum study of inebilizumab
-
4:26
bruce cree, md, phd, mas: the nmosd landscape after the inebilizumab approval
-
4:04
day-to-day care of nmosd, advances and challenges: bruce cree, md, phd, mas, faan
-
7:33
degenerative changes of the lumbar spine on mri
-
28:40
michalis pagkalos - introducing dendritic computations to snns with dendrify
-
49:38
neurology series: ms and neuroinflammatory disorders
-
3:55
bruce cree, md, phd, mas: exploring clinical utility of siponimod, fingolimod in ms
-
0:56
bruce cree – ectrims 2022
-
3:12
analyzing long term, end of study results for inebilizumab treatment in nmosd
-
4:04
long term benefits of inebilizumab revealed in n momentum analysis
-
2:44
updates on n-momentum: inebilizumab versus placebo in patients with nmosd
-
2:27
key considerations for clinicians treating nmosd
-
2:00
bruce cree, md, phd: long-term data collection in ms studies
-
3:03
how do the approved nmosd therapies work?
-
3:22
aan 2021 highlights: two-year efficacy and safety data with inebilizumab to treat nmosd
-
3:35
the payer dilemma with accessing effective therapies for nmosd
-
2:55
vaccine status and hypogammaglobulinemia in n-momentum trial analyses
-
4:38
inebilizumab as a potential therapy for autoimmune encephalitis
-
2:16
bruce cree, md, phd: brain volume loss and disability progression in ms
-
57:39
advances in s1pr modulation: progress in understanding brain atrophy and cognition measures in ms